Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer

 

 Permissions and Reprints

Abstract

The AGO Kommission Ovar already published a statement in 2013, warning about the uncritical use of hyperthermic intraperitoneal chemotherapy (HIPEC) outside controlled studies. This statement has now been updated after the most recent literature was reviewed by AGO Kommission Ovar, the AGO Study Group, NOGGO, AGO Austria and AGO Switzerland. The authors conclude that HIPEC remains experimental. Its use is not recommended and should be rejected outside of prospective controlled trials.

Zusammenfassung

Bereits in 2013 wurde eine Stellungnahme der AGO Kommission Ovar, die vor dem unkritischen Einsatz der HIPEC außerhalb von kontrollierten Studien gewarnt hat, publiziert. Unter Würdigung der seither erschienenen Literatur wurde diese Stellungnahme nun gemeinsam von der Kommission Ovar, der AGO Studiengruppe, NOGGO, AGO Österreich und AGO Schweiz aktualisiert. Zusammenfassend kommen die Autoren zu dem Ergebnis, dass die HIPEC auch weiterhin als experimentell zu bewerten ist und ein Einsatz außerhalb von prospektiven, kontrollierten Studien nicht zu empfehlen und abzulehnen ist.

• References

• 1 Wagner U, Harter P, Hilpert F et al. S3-Guideline on diagnostics, therapy and follow-up of malignant ovarian tumors. Geburtsh Frauenheilk 2013; 73: 874-889
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Harter P, Mahner S, Hilpert F et al. Statement by the Kommission OVAR of the AGO Study Group on the use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to treat primary and recurrent ovarian cancer. Geburtsh Frauenheilk 2013; 73: 221-223
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Möbus V, Wandt H, Frickhofen N et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 2007; 25: 4187-4193
  CrossrefPubMedGoogle Scholar
• 4 Zivanovic O, Abramian A, Kullmann M et al. HIPEC ROC I: A phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer 2014; 136: 699-708
  PubMedGoogle Scholar
• 5 Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28: 3323-3329
  CrossrefPubMedGoogle Scholar
• 6 Aghajanian C, Blank SV, Goff BA et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or Fallopian tube cancer. J Clin Oncol 2012; 30: 2039-2045
  CrossrefPubMedGoogle Scholar
• 7 Lee CK, Lord S, Grunewald T et al. Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. Gynecol Oncol 2015; 136: 18-24
  CrossrefPubMedGoogle Scholar
• 8 Harter P, Beutel B, Alesina PF et al. Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecol Oncol 2014; 132: 537-541
  CrossrefPubMedGoogle Scholar
• 9 Konigsrainer I, Horvath P, Struller F et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience. Langenbecks Arch Surg 2014; 399: 589-594
  CrossrefPubMedGoogle Scholar
• 10 Chi DS, McCaughty K, Diaz JP et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006; 106: 1933-1939
  CrossrefPubMedGoogle Scholar
• 11 Sehouli J, Richter R, Braicu EI et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol 2010; 102: 656-662
  CrossrefPubMedGoogle Scholar
• 12 Harter P, du Bois A, Hahmann M et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; 13: 1702-1710
  CrossrefPubMedGoogle Scholar
• 13 Oksefjell H, Sandstad B, Tropé C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 2009; 20: 286-293
  PubMedGoogle Scholar
• 14 Tian WJ, Jiang R, Cheng X et al. Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1–1 cm after secondary cytoreduction. J Surg Oncol 2010; 101: 244-250
  PubMedGoogle Scholar
• 15 Chiva LM, Gonzalez-Martin A. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol 2015; 136: 130-135
  CrossrefPubMedGoogle Scholar
• 16 Kisser A, Kirisits A. Hypertherme intraperitoneale Chemotherapie bei Peritonealkarzinose solider abdominaler Tumore. Decision Support Dokument Nr. 74. Wien: Ludwig Boltzmann Institut für Health Technology Assessment; 2013
  Google Scholar

• Supplementary Material